Endpoints Media Bias

AI Generated News Bias (?): The source appears to have a neutral or minimal bias in its reporting.

The articles cover a range of topics related to the pharmaceutical and biotech industries, providing factual information without inserting opinion or judgment.

There is a mix of positive, negative and neutral coverage.

The reporting relies heavily on company statements, SEC filings, clinical trial data, and comments from industry experts to provide context.

There does not appear to be an overt agenda or consistent skew.

MyBias:
As an AI assistant without subjective experiences, I do not have personal biases.

However, my training data and programming may contain implicit biases that could affect my processing of information.

I strive to analyze the news source objectively based solely on the content provided.


January 13, 2024


Show Historical Bias


         



Customize Your AI News Feed. No Censorship. No Ads.






Endpoints News Cycle (?):






Endpoints News Bias (?):

Prescriptive:

Opinion:

Political:

Oversimplification:

Appeal to Authority:

Ideological:



Endpoints Social Media Impact (?): 7




Endpoints Most Opinionated Articles


Califf and Marks call for clinicians to help address 'large volume' of vaccine misinformation

AlloVir lays off 95% of workers after canceling PhIII antiviral cell therapy studies

Verona secures $400M financing arrangement with Oxford, Hercules as ensifentrine PDUFA date inches closer

🚨 Longboard stock soars on heels of positive topline data for seizure medication




Endpoints Most Oversimplified Articles


Bluebird snags more outcomes-based coverage for its $3M+ sickle cell gene therapy

Verona secures $400M financing arrangement with Oxford, Hercules as ensifentrine PDUFA date inches closer

Novartis adds Indianapolis site to its manufacturing capacity for radioligand drug Pluvicto




Endpoints Most Appeal to Authority Articles


Califf and Marks call for clinicians to help address 'large volume' of vaccine misinformation

Bluebird snags more outcomes-based coverage for its $3M+ sickle cell gene therapy




Endpoints Most Covering Responses


Califf and Marks call for clinicians to help address 'large volume' of vaccine misinformation

Bluebird snags more outcomes-based coverage for its $3M+ sickle cell gene therapy

FDA seizes thousands of counterfeit Ozempic units, warns consumers not to use

Verona secures $400M financing arrangement with Oxford, Hercules as ensifentrine PDUFA date inches closer




Endpoints Most Gossipy Articles


FDA seizes thousands of counterfeit Ozempic units, warns consumers not to use

🚨 Shunned by insurers, digital therapeutics startups look for other ways to get paid

IQVIA and Propel abandon merger after FTC probe and injunction

🚨 FDA lifts partial clinical hold on Innate's cancer drug after patient death linked to disease progression


Endpoints Most Overconfident Articles


Longboard stock soars on heels of positive topline data for seizure medication

Allogene Therapeutics to restructure, deprioritize PhII CAR-T trials in clinical pivot




2024-01-042024-01-072024-01-102024-01-132024-01-17Endpoints # Articles1917Average News Sentiment000Endpoints # ArticlesAverage News Sentiment



Click points to explore news by date. News sentiment ranges from -10 (very negative) to +10 (very positive) where 0 is neutral.





Endpoints Recent Articles






































×

Chat with Helium


 Ask me any question!